Regentis Biomaterials Advances Simplified Cartilage Repair Platform Toward Key Milestones
Regentis Biomaterials is moving its cell-free hydrogel implant GelrinC toward U.S. market entry, targeting a $3 billion knee cartilage repair market with a simplified procedure that could replace traditional microfracture and cell-based therapies.
Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing its GelrinC® hydrogel implant toward key commercial milestones, aiming to simplify knee cartilage repair with a single-step, approximately 10-minute procedure. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists.
GelrinC® is a cell-free, off-the-shelf hydrogel designed to regenerate damaged knee cartilage in a controlled process. According to the company, clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. The implant has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled.
The company is positioning for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission. This timeline could bring a new treatment option to patients who currently lack an off-the-shelf regenerative therapy for knee cartilage repair.
To view a full corporate profile, visit this link.
Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing innovative tissue repair solutions. Its Gelrin platform technology uses synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC® is the lead product, aiming to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer.